Enanta Pharmaceutica Up 20.58% To $10.78 After Earnings Beat

Enanta Pharmaceutica (ENTA) said after close Monday that it lost $1.33 per share in quarter four 2023.

On the revenue line, the company reported $18.9 million, beating estimates by $1.4 million.

In the same quarter a year ago, the company lost $1.27 per share on revenue of $20.3 million.

The stock is up 20.58% to $10.78 after the report.

Despite Enanta Pharmaceutica reporting a decline in revenues, earnings increased signaling a rise in profit margins.

Wall Street Analysts had an average rating of Hold on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 38. Meanwhile, the average Wall Street analyst rated the stock a Hold.

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.